Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462720 · ClinicalTrials.gov registry record · Phase 4
COMFORT: A Multicenter, Open-label, Randomized, Crossover Study
A Phase 4 study of Varicose Veins, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 4
- Study locations
NCT02462720: Completed Phase 4 study of Varicose Veins, sponsored by Boston Scientific Corporation.
NCT02462720 is a Phase 4 study of Varicose Veins that has completed, run by Boston Scientific Corporation. The registered enrollment target is 35 participants, below the 164-participant average among 6 other Varicose Veins trials with a reported enrollment target (79% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02462720, a Phase 4 study of Varicose Veins, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to evaluate pain the patient experienced following treatment of varicose veins with Varithena® compared to radiofrequency ablation.
Primary Outcome
14-day average post-treatment pain using a VAS pain score. VAS pain score is an integer-valued, interval scale variable with range from 0 to 100 representing the spectrum from no pain to pain as bad as one can imagine.
Conditions Studied
Interventions
- DEVICE Radiofrequency ablation
- DRUG Varithena®
Study Locations (4)
Florida
- Coastal Vascular and Interventional, PLLC - Pensacola
Illinois
- Midwest Institute for Minimally Invasive Therapies - Melrose Park
New York
- Venous Institute of Buffalo - Amherst
Washington
- Lake Washington Vascular - Bellevue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-03 |
| Phase | Phase 4 |
What the finished NCT02462720 record still lists
NCT02462720 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 164-participant average among 6 other Varicose Veins trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Varicose Veins appearing as the primary indexed condition, and to 2 interventions - of which Radiofrequency ablation is the first listed.
NCT02462720 reports a single indexed study location in Florida, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT02462720 about?
NCT02462720 is a clinical study titled "COMFORT: A Multicenter, Open-label, Randomized, Crossover Study". The purpose of this study is to evaluate pain the patient experienced following treatment of varicose veins with Varithena® compared to radiofrequency ablation.
What is the current status of trial NCT02462720?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2015-05. Estimated completion is 2016-03.
What conditions does trial NCT02462720 study?
This clinical trial studies the following conditions: Varicose Veins.
What interventions are being tested in trial NCT02462720?
The interventions under investigation include: Radiofrequency ablation (DEVICE), Varithena® (DRUG).
Who is sponsoring clinical trial NCT02462720?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02462720 being conducted?
This trial has 4 study locations across Florida, Illinois, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Varicose Veins
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence
COMPLETED · Phase 3
-
An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins
COMPLETED · Phase 2
-
Retrospective Review of Saphenous Vein Incompetence: Venaseal Versus Endovenous Thermal Ablation
COMPLETED
-
Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence
COMPLETED · Phase 2
-
Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)
COMPLETED · Phase 1
-
Prevalence of MTHFR Polymorphisms in Venous Disease
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia